Enliven Therapeutics, Inc. (ELVN)
27.86
+0.66
(+2.41%)
USD |
NASDAQ |
Jan 22, 11:53
Enliven Therapeutics Shareholders Equity (Quarterly): 476.12M for Sept. 30, 2025
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Coherus Oncology, Inc. | 87.77M |
| Allogene Therapeutics, Inc. | 315.33M |
| Pyxis Oncology, Inc. | 68.78M |
| CEL-SCI Corp. | 15.96M |
| AIM ImmunoTech, Inc. | -6.077M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 490.88M |
| Total Liabilities (Quarterly) | 14.75M |
| Debt to Equity Ratio | 0.0008 |
| Current Ratio | 32.95 |
| Net Debt Paydown Yield | -0.00% |